Matt Kapusta is the founder of UniQure. UniQure has raised $300M in total funding. Latest round: IPO.
Matt Kapusta serves as the CEO of uniQure, a biotechnology company established over 20 years ago, recognized as a pioneer in gene therapy. The company's mission is to develop one-time administered gene therapies for patients with devastating and often incurable diseases, focusing on CNS disorders and liver-based diseases. uniQure aims to revolutionize treatment through gene therapy and has invested significantly in internal manufacturing capabilities, operating an 80,000-square-foot facility in Lexington, Massachusetts. They have lead programs in hemophilia and Huntington's disease, along with other programs in their research pipeline.
Full founder directory · Investor directory · Company funding database · Fundraising library